Computational approaches: Discovery of GTPase HRas as prospective drug target for 1,3-diazine scaffolds

• Published in: BMC Chemistry
• Main Author: Kumar S.; Sharma D.; Narasimhan B.; Ramasamy K.; Shah S.A.A.; Lim S.M.; Mani V.
• Format: Article
• Language: English
• Published: BioMed Central Ltd 2019
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077108304&doi=10.1186%2fs13065-019-0613-8&partnerID=40&md5=4a6692550e891a186ab1ee1e0c1119e9

Heterocyclic 1,3-diazine nucleus is a valuable pharmacophore in the field of medicinal chemistry and exhibit a wide spectrum of biological activities. PharmMapper, a robust online tool used for establishing the target proteins based on reverse pharmacophore mapping. PharmMapper study is carried out to explore the pharmacological activity of 1,3-diazine derivatives using reverse docking program. PharmMapper, an open web server was used to recognize for all the feasible target proteins for the developed compounds through reverse pharmacophore mapping. The results were analyzed via molecular docking with maestro v11.5 (Schrodinger 2018-1) using GTPase HRas as possible target. The molecular docking studies displayed the binding behavior of 1,3-diazine within GTP binding pocket. From the docking study compounds s3 and s14 showed better docked score with anticancer potency against cancer cell line (HCT116). Hence, the GTPase HRas may be the possible target of 1,3-diazine derivatives for their anticancer activity where the retrieved information may be quite useful for developing rational drug designing. Furthermore the selected 1,3-diazine compounds were evaluated for their in vitro anticancer activity against murine macrophages cell line. 1,3-Diazine compounds exhibited good selectivity of the compounds towards the human colorectal carcinoma cell line instead of the murine macrophages. The toxicity study of the most active compounds was also performed on non cancerous HEK-293 cell line. © 2019 BioMed Central Ltd.. All rights reserved.